| Click on "►" to expand:|
 BRAND NAMES
- International: Alphagan
 MECHANISM OF ACTION
Brimonidine is an α2 adrenergic agonist. It significantly lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. It has a peak ocular hypotensive effect occurring at two hours post-dosing.
Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The recommended dose is one drop in the affected eye(s) three times daily.
If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.
- Hypersensitivity to brimonidine or any component
- Patients receiving monoamine oxidase inhibitors
- Measure intraocular pressures routinely
- Brimonidine may cause fatigue and /or drowsiness in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness.
- May reduce pulse and blood presure. Caution in using concomitant drugs such as anti-hypertensives especially beta blockers and/or cardiac glycosides is advised
 PREGNANCY AND LACTATION
- Pregnancy Category B (US). Brimonidine should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
- Nursing Mothers: It is not known whether this drug is excreted in human milk; although in animal studies brimonidine was excreted in breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother
 SIDE EFFECTS
Possible adverse reactions include: headache, fatigue, drowsiness, decreased alertness, dizziness, allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.